LIVE WEBINAR
Applying Adimab's Diverse Tools for Novel T Cell Engagers
See how Adimab's proprietary T cell binders and heterodimerization solutions accelerate the design and development of multispecific T cell engagers.
December 3, 2026
2:00 pm ET
Online • Free to attend
About the webinar
Currently approved monospecific antibodies are often not effective enough for every patient or indication. As a result, the immunotherapy field is expanding toward molecules that engage multiple signaling pathways and cell types at once.
Adimab's proprietary αCD3, αCD28, and αTCR binders, combined with our novel heterodimerization solutions, enable partners to accelerate the design and development of T cell engagers (TCEs).
In this webinar, William Roach will demonstrate these capabilities through multispecifics that leverage Adimab's optimized T cell engager antibody panels.
PRESENTER
William Roach, PhD
Senior Director, Technology Alliances | Adimab
William earned his PhD in Cell and Molecular Biology from Washington University in St. Louis and completed postdoctoral training in Biochemistry at Dartmouth College. He then joined Adimab in 2008 in antibody engineering, focusing on building the platform and executing discovery and engineering programs. He subsequently moved into the Strategic Alliances and Business Development group and focuses on establishing new partnerships and strategically monitoring the biologics landscape.
About Adimab
Adimab is the most successful antibody discovery and engineering company in the industry and the partner of choice for biopharma. Since 2007, we’ve collaborated with more than 140 partners in global pharma, cutting-edge biotech, and leading academic institutions to generate high-quality therapeutic leads across a wide range of targets and formats. Together, we’ve completed more than 675 discovery campaigns, yielding over 90 clinical programs and six commercial products.
Our proprietary yeast-based platform enables end-to-end discovery, optimization, and developability assessment, reliably and efficiently delivering fully human IgGs, HCAbs, multispecifics, and other protein-based modalities, including TCRs.
Questions about partnering? Contact our business development team at bd@adimab.com.